Human sSELP (Soluble P-Selectin) ELISA Kit

Magnetic nanocomposite films, comprised of a genetically engineered silk-elastin-like protein (SELP) and CoFe2O4 nanoparticles (CFO NPs) with concentrations varying between 5 and 20 wt%, were produced by solvent casting. The obtained materials were analysed regarding their morphology, physical-chemical, thermal, mechanical and magnetic properties. It was found that the magnetic NPs are homogenously distributed among the film and do not induce any significant alterations in their physical-chemical properties. Regarding the thermal properties, the onset degradation temperature of the SELP-59-A films was also not significantly altered by the inclusion of the NPs. Further, strongly bound water is present in the material, which decreases with increasing NPs concentration. Likewise, the mechanical properties of the films were affected by the presence of NPs. Finally, it was demonstrated that the magnetization saturation increases with increasing CFO NPs content, showing the magnetic responsivity of the materials and opening new perspectives in the development of a new generation of multifunctional biocomposites suitable for a wide range of applications, from sensors to tissue engineering.

Thrombosis is a major cause of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET). The pathophysiology of thrombosis in these disorders remains unclear, and we hypothesized that upregulation of thrombotic, inflammatory, and hypoxia-inducible factor (HIF)-regulated genes may play a role in it. We performed unbiased RNA sequencing in granulocytes and platelets of PV patients and found differential expression of several thrombotic, inflammatory, and HIF-regulated genes. The expression of many of these genes positively correlated with JAK2 expression and JAK2(V617F) allelic burden. We then validated these findings by quantitative polymerase chain reaction analyses of selected gene transcripts in a larger number of PV and ET granulocytes and platelets (58 patients) and in 28 controls, and we compared these findings in patients with and without thrombosis. The study included 29 females and 29 males; of these, 28 had a history of thrombosis. We found that transcripts of several selected genes were upregulated in patients with PV or ET compared with controls. In granulocytes, the expression levels of F3, SELP, VEGFA, and SLC2A1 were significantly higher in patients with a history of thrombosis compared with those who did not have thrombosis. Patients with a history of thrombosis have significantly higher expression of IL1RAP (P < .05) in platelets compared with those without thrombosis. Our study confirms the presence of a thromboinflammatory state and augmented HIF activity in PV and ET and its role in thrombosis. These data may provide the background for targeted therapies in PV and ET.